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Percutaneous Computed Tomography-guided
Cryotherapy of Thoracic Masses in Nonsurgical
Candidates: Experience in 19 Patients
Siu-Cheung Chan,1,5* Hui-Ping Liu,2 Winnie Chiu-Wing Chu,3 Tzu-Ping Chen4,5
Background/Purpose: Percutaneous cryotherapy has become a minimally invasive treatment option for
unresectable lung malignancies. We report the experience and outcomes with percutaneous computed 
tomography (CT)-guided cryotherapy of primary lung malignancies, as well as recurrence and metastases,
in patients ineligible for surgery.
Methods: The procedure was performed after administration of local anesthesia on 23 tumors in 19 patients
(10 male and 9 female patients; mean age, 58.7 years). None of the patients were surgical candidates and un-
derwent CT-guided percutaneous cryotherapy for treatment of the malignant mass in the lung. Visualization
of low-attenuation ice ball formation was performed using CT scanning after each cycle of freezing and thaw-
ing therapy. Subsequent CT scans were scheduled at 3-month intervals post-procedure to assess tumor control.
Results: No lethal complication, major bleeding or bronchial damage was observed in any of the 23-
cryotherapy sessions performed. Three patients developed pneumothorax and one patient required chest tube
insertion. Thirteen tumors (56.5%) regressed, including two complete responses, five tumors (21.7%) were
stationary and the remaining five tumors (21.7%) were found to be progressing at the 3-month follow-ups.
No recurrence was found in the 11 regressed tumors for 6 months, and there was also no recurrence in the
two tumors that completely responded up to 12 months later with a satisfactory procedure.
Conclusion: Percutaneous cryotherapy for primary lung cancer, recurrence and metastatic lung tumors is
feasible and safe for local control.
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Percutaneous cryotherapy is recommended for 
a range of anatomic and tumor treatment options
because of its low pain, good ice visualization,
and preservation of collagenous tissue architecture.
Cryotherapy has been performed in the liver, pros-
tate, kidney, and breast with good outcomes.1–4
In patients in whom the lung tumor is inaccessible
through the tracheobronchial tree, and surgical
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resection is not indicated, oncological treatment
of large tumors is often of limited benefit. There-
fore, treatment options are severely restricted.1
Computed tomography (CT)-guided percutaneous
cryotherapy of lung malignancy is considered for
patients ineligible for surgery, and a metastatic
tumor is associated with low procedural morbid-
ity.5 Cryotherapy causes coagulation necrosis con-
fined to the tissues within the region of probe
application, and ice-ball formation occurs as a
result of the dehydration caused by the intracellu-
lar ice crystals that form at very low temperatures.
This leads to protein denaturation and solute tox-
icity within the cells.6,7 The extent and degree of
tissue destruction correlate with the size of the
ice ball and the temperature within it. The latest
generation of cryotherapy machines use the Joule-
Thomson effect, in which different gases undergo
unique temperature changes when depressurized,
according to unique gas coefficients. The proper-
ties of argon make it useful for cooling to below
−180ºC, whereas helium is ideal for thawing and
re-warming. The use of gas allows for rapid tran-
sition from freezing to defrosting, which facili-
tates tighter control, as well as expedition of the
procedure.8 Based on the biological effect of ex-
treme cold, a lethal temperature of approximately
−100ºC at the tumor level is required to achieve
total destruction of tumors 2 cm or larger in di-
ameter.9 We performed percutaneous cryotherapy
under CT guidance with local anesthesia as a lo-
cally curative treatment for unresectable lung tu-
mors. Twenty-three cryotherapy procedures were
performed successfully in 19 patients, with tissue
proof of unresected primary lung malignancy, 
recurrent lung malignancy and lung metastasis.
Materials and Methods
Patients
The institutional review board of our hospital 
approved this retrospective study and informed
consent was waived due to the retrospective and
anonymous nature of the analysis. A total of 23
pulmonary masses in 19 patients (10 male and 
9 female patients; mean age, 58.7 years; age range,
19–77 years) were treated with cryotherapy be-
tween October 2007 and September 2009. Five pa-
tients had unresectable non-small cell lung cancer,
six had non-small cell lung cancer after lobectomy
with recurrence, and the remaining eight patients
had lung metastasis. The patients were considered
ineligible for surgery or had undergone other lung
cancer therapies that were unsuccessful. All of the
patients met at least one of the following inclu-
sion criteria: (1) single or multiple peripheral lung
masses larger than 1 cm but less than 5 cm in di-
ameter, with previous therapies (radiation ther-
apy, chemotherapy, and/or surgery) having failed;
(2) a nonresectable central lung cancer (as deter-
mined by means of surgical consultation, accord-
ing to size, stage or health status); (3) fewer than
five metastatic tumors; and (4) a mass or adenopa-
thy involving the mediastinum and/or the peri-
cardium without distant metastasis. The latter was
considered as an inclusion criterion only when it
was associated with a distant measurable primary
lung tumor.
Cryotherapy technique
The location and size of tumors were noted at
preoperative evaluation. A tumor was considered
a central mass if it abutted any of the mediastinal
or hilar structures. Tumor measurements were ob-
tained in two dimensions on CT images, at the
level of the tumor’s most prominent appearance in
the transverse plane. Patients were placed feet first
into the CT gantry for better cryoprobe access.
Cryotherapy was performed after administra-
tion of local anesthesia by one thoracic surgeon
and one radiologist. For sedation, the patients re-
ceived 50 mg pethidine (Demoral; Roche, Basel,
Switzerland) and 5 mg midazolam (Dormicum;
Roche, Basel, Switzerland).
A 21-gauge 15-cm needle was inserted into the
center of each mass under CT-guidance (Light
speed VCT, GE Medical System, Milwaukee, WI,
USA), and used as a guide for subsequent insertion
of cryoprobes. The cryoprobe used was a PERC24
(Endocare, Irvine, CA, USA), it was 2.4 mm in 
diameter and it was inserted directly into the 
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patient. The cryosurgical unit, the Cryocare Surgical
System (Endocare), offers a “stick” function for
fixating a probe’s position once it is inserted into
the tumor. This maximized accuracy when multi-
ple cryoprobes were placed.
Cryoablation is achieved using high-pressure
argon and helium gas for freezing and thawing,
respectively, based on the Joule-Thompson prin-
ciple. Rapid freezing of tissue with a cryoprobe 
is based on the rapid expansion of argon gas in 
a sealed probe with a distal uninsulated portion.
This process results in rapid cooling to −100ºC
within a few seconds. Active thawing of the ice
ball is achieved by introducing helium gas into
the probes instead of argon gas. The cryoablation
procedure we used consisted of two cycles of 
10 minutes of freezing and a 5-minute active thaw
between the cycles. During freezing, ice ball growth
and tumor coverage were monitored at 5-minute
intervals by CT scan. For a mass within the lung
tissue, a 2.4-mm cryoprobe can generate an ice
ball up to 3.7 cm in diameter and up to 5.7 cm
along the probe shaft. For this reason, a single
cryoprobe was placed for tumors 2 cm or less in
diameter. An additional cryoprobe was used for
larger tumors to ensure that an adequate freezing
margin of 5–10 mm was achieved. After comple-
tion of the final freeze in the cryotherapy proce-
dure, the cryoprobes were warmed by helium gas
until the temperature was higher than 20ºC. The
cryoprobes were then withdrawn.
Post-procedural evaluation
Immediately after the cryoprobes were removed,
the patient was placed back into the CT gantry for
scanning and measurement of the low-attenuation
ice ball formation. All CT scans obtained after the
percutaneous cryoablation were acquired within
2–3 minutes of termination of freezing; the visible
size of the ice ball remains relatively unchanged
during this time.2,10,11 A repeat CT scan was per-
formed 24 hours after the procedure to evaluate
the type and frequency of complications.
Follow-up helical CT scans of patients were
performed at 3 months post-procedure. Changes
in tumors following cryotherapy were measured
using the Response Evaluation Criteria in Solid
Tumors (RECIST) protocol,12,13 which is based on
objective measurements of lesion size before and
after treatment. “Complete response” (CR) indica-
tes disappearance of the lesion, “partial response”
(PR) is a decrease of at least 30% in the sum of the
longest diameter of target lesions, “progressive
disease“ (PD) is an increase of at least 20% in the
sum of the longest diameter of target lesions, and
“stable disease” (SD) is neither sufficient shrink-
age to qualify for partial response nor a sufficient
increase to qualify for progressive disease.
Results
A total of 23 pulmonary masses in 19 patients
were treated with cryotherapy. In all cases, cryo-
therapy was performed percutaneously under CT
guidance with local anesthesia without major
complications. Complications are listed in Table 1.
The mean hospital stay after treatment was 2.8 days
(range, 2–9 days). There were no treatment-related
deaths or conversions to surgical intervention.
The responses to cryotherapy, measured using
the RECIST protocol, are listed in Table 2. We 
observed a CR in two (8.7%) tumors, PR in 11
(47.8%) tumors, SD in five (21.7%) tumors and
PD in five (21.7%) tumors, giving a response rate
of 56.5% (Figures 1 and 2).
Discussion
Percutaneous cryotherapy of lung masses is tech-
nically feasible and may provide an important
Table 1. Complications after cryoablation
Complications n (%)
Pneumothorax 4 (17.4)
Chest tube 1 (4.3)
Observation 3 (13)
Hemoptysis (without additional treatment) 4 (17.4)
Pleural effusion (without additional 3 (13)
treatment)
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treatment alternative when other treatments do
not yield sufficient local tumor control.14 The
ability to visualize a low-attenuating ice ball as it
thoroughly covers a soft tissue tumor mass during
the freeze cycles is a potential benefit that is not
available with heat-based treatment.
Cryotherapy kills cells and ablates tissue by
direct cell injury resulting from ice crystal forma-
tion and related deleterious effects, as well as vas-
cular stasis caused by microcirculatory failure. As
temperatures fall, direct cellular injury occurs as
a result of cellular metabolism failure. When the
temperature reaches −20ºC, water in the extra-
cellular environment crystallizes into ice, and with-
drawal of the water from the system results in a
hyperosmotic extracellular environment. Conse-
quently, denaturation and electrolyte imbalances
occur.15,16 During thawing, ice crystals fuse to
form larger crystals, which eventually disrupt the
cell membrane, which is another pathway for
causing cell injury. Gage and Baust recommend a
minimum freezing temperature of −40ºC for at
least 3 minutes for complete eradication of the tu-
mor and a minimum of two freeze-thaw cycles.15,16
This leads to modification of cryotherapy tech-
niques, in turn leading to improved biochemical
and histological outcomes.17
In our series, the response of the lung masses
was evaluated using the RECIST protocol. In the
11 (47.8%) of 23 tumors diagnosed as PR, local
Table 2. Radiographic response and clinical result
Patient 
Nodules Each tumor’s 
Clinical outcome (prognosis after 
Primary tumor treated with response after 
no.
cryotherapya 3 mob
initial cryotherapy)
1 Alveolar soft part sarcoma 2 CR
of the thigh PR Stationary (24 POM)
2 Recurrent NSCLC 1 PR Stationary (18 POM)
3 Recurrent NSCLC 1 PD Progression (3 POM, 9 POM dead)
4 Recurrent NSCLC 1 SD Liver metastasis (19 POM alive)
5 Recurrent NSCLC 1 PR New pulmonary nodule (16 POM alive)
6 Liposarcoma of the chest wall 2 SD, SD Stationary (17 POM)
7 Esophageal cancer 2 PR, PR New pulmonary nodule (7 POM, 
15 POM dead)
8 Rectal cancer 1 PR Liver metastasis (7 POM alive under 
chemotherapy)
9 NSCLC 1 PR New pulmonary nodule and multiple 
metastasis (10 POM, alive)
10 NSCLC 1 PR Stationary (16 POM)
11 NSCLC 1 PR Focal regression
New pulmonary nodule (6 POM alive)
12 NSCLC 1 PD Died at 4 POM
13 Recurrent NSCLC 1 CR Disease-free at 14 POM
14 Osteogenic sarcoma 2 PD, PD Progression (3 POM alive)
15 NSCLC 1 SD Stationary (6 POM)
16 Recurrent NSCLC 1 PD Progression and new pulmonary 
nodule (3 POM alive)
17 Colon cancer 1 PR Regression (6 POM)
18 High-grade sarcoma of the thigh 1 PR Regression (6 POM)
19 Renal cell carcinoma 1 SD Stationary (6 POM)
aTotal pulmonary nodules (n = 23); bCR (n = 2, 8.7%), PR (n = 11, 47.8%), SD (n = 5, 21.7%), and PD (n = 5, 21.7%). CR = complete 
regression; PR = partial response; SD = stable disease; PD = progressive disease; POM = post operative months; NSCLC = non-small cell
lung cancer.
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recurrence did not occur during more than 
6 months of follow-up. In the two (8.7%) of 23
tumors diagnosed as CR, there was no recurrence
during 12 months of follow-up; therefore, our
series had a response rate of 56.5%.
Cryotherapy offers the opportunity to have ex-
cellent healing and resistance to infection. The
cryogenic lesion is an anesthetic lesion that ini-
tially shows minimal surrounding edema or in-
flammation.15,16 Because of this localized effect,
cryotherapy is a well-tolerated procedure. These
lesions, which have been found to be relatively
resistant to infection, show excellent healing, with
minimal scar formation and preservation of tissue
planes.15,16
We achieved our major treatment goals of
using local sedation during the procedures and
preserving underlying tissue architecture with
minimal complications. Because metastatic lung
tumors may associate with other latent metastatic
lesions in the lung, pulmonary reserve after treat-
ment can be important. Greater pulmonary reserve
is expected after cryotherapy, when applied to cen-
trally located tumors than after surgical procedures
such as lobectomy, which is usually required for
resection of such tumors.
In conclusion, percutaneous CT-guided cryo-
therapy offers a viable alternative for a nonsur-
gical lung mass, because it is minimally invasive
and uses local anesthesia, with satisfactory local
control. It preserves respiratory function and 
is well tolerated by the patient. The procedure
demands careful patient selection and technical 
expertise to achieve satisfactory cancer control,
patient satisfaction, and acceptable quality of
life.
A B
C D
Figure 1. (A) A 1.5-cm lung nodule in the Right lower lobe (RLL) caused by lung metastasis due to recurrent alveolar soft
part sarcoma. (B) The RLL nodule is being treated from the lateral approach. One cryoprobe is seen bracketing the nod-
ule. Ten minutes after the beginning of second freezing, an ice ball with hazy consolidation can be seen surrounding the
RLL nodule. (C) Complete resolution of the RLL nodule with linear scarring was observed 3 months after the procedure.
(D) At the 12-month follow-up, complete resolution of the RLL and no recurrence or residual tumor were observed.
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